These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 32282772)
1. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure. Matsumoto T; Kurioka Y; Okazaki U; Matsuo Y; Kimura S; Miura K; Tsuduki T; Takagi S; Takatani M; Morishita H Pancreas; 2020 Apr; 49(4):574-578. PubMed ID: 32282772 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765 [TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Kim S; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Ung B; Parisi M; Marshall JL Adv Ther; 2018 Oct; 35(10):1564-1577. PubMed ID: 30209750 [TBL] [Abstract][Full Text] [Related]
4. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Lee JC; Woo SM; Shin DW; Kim J; Yang SY; Kim MJ; Kim JW; Kim JW; Lee WJ; Cha HS; Park P; Kim J; Hwang JH Am J Clin Oncol; 2020 Sep; 43(9):654-659. PubMed ID: 32889836 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Arima S; Kawahira M; Shimokawa M; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Taguchi H; Honda T; Shibuki T; Mitsugi K; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Otsuka T Pancreas; 2021 Aug; 50(7):957-964. PubMed ID: 34347735 [TBL] [Abstract][Full Text] [Related]
6. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762 [TBL] [Abstract][Full Text] [Related]
7. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching. Mie T; Sasaki T; Takeda T; Fukuda K; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N Pancreas; 2021 Apr; 50(4):595-601. PubMed ID: 33939674 [TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727 [TBL] [Abstract][Full Text] [Related]
10. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547 [TBL] [Abstract][Full Text] [Related]
11. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Rapposelli IG; Casadei-Gardini A; Vivaldi C; Bartolini G; Bernardini L; Passardi A; Frassineti GL; Massa V; Cucchetti A Biomolecules; 2021 May; 11(6):. PubMed ID: 34067288 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545 [TBL] [Abstract][Full Text] [Related]
13. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
14. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. Papneja N; Zaidi A; Chalchal H; Moser M; Tan K; Olson C; Haider K; Shaw J; Ahmed S Pancreas; 2019 Aug; 48(7):920-926. PubMed ID: 31180981 [TBL] [Abstract][Full Text] [Related]
15. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766 [TBL] [Abstract][Full Text] [Related]
16. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J; Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182 [TBL] [Abstract][Full Text] [Related]
18. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170 [TBL] [Abstract][Full Text] [Related]
19. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232 [TBL] [Abstract][Full Text] [Related]
20. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]